Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT

Ferdinando Calabria, Agostino Chiaravalloti, Barbara Di Pietro, Cristina Grasso, Orazio Schillaci

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The objective of this study was to give an overview of the potential clinical utility of [ 18F]-L-dihydroxyphenylalanine ( 18F-DOPA) PET and PET/CT for imaging of brain tumors. Review articles and reference lists were used to supplement the search findings. 18F-DOPA has been investigated as a PET tracer for primary brain tumors, metastases of somatic cancer, and evaluation of relapse of pathology in patients with brain tumor after surgery and/or radiotherapy on the basis of enhanced cell proliferation. Available studies have provided encouraging preliminary results for diagnosis of brain tumors and relapse after surgery/radiotherapy. In the brain, excellent discrimination between tumor and normal tissue can be achieved because of the low physiological uptake of 18F-DOPA and the high ratio between tumor and normal hemispheric tissue. Information on evaluation of brain metastases is limited but encouraging. PET and PET/CT with 18F-DOPA are useful in diagnosing primary brain tumors and should be recommended in the diagnosis of relapse of disease after surgical treatment and/or radiotherapy. Semiquantitative analysis could improve diagnosis while correlative imaging with MRI is essential. Limits are due to low knowledge of potential pitfalls.

Original languageEnglish
Pages (from-to)563-570
Number of pages8
JournalNuclear Medicine Communications
Volume33
Issue number6
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Dihydroxyphenylalanine
Molecular Imaging
Brain Neoplasms
Radiotherapy
Recurrence
Neoplasm Metastasis
Neoplasms
Brain
Cell Proliferation
Pathology

Keywords

  • [ F]-L-dihydroxyphenylalanine
  • brain metastases
  • brain tumors
  • molecular imaging
  • PET/CT
  • recurrence

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Calabria, F., Chiaravalloti, A., Di Pietro, B., Grasso, C., & Schillaci, O. (2012). Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT. Nuclear Medicine Communications, 33(6), 563-570. https://doi.org/10.1097/MNM.0b013e328351d566

Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT. / Calabria, Ferdinando; Chiaravalloti, Agostino; Di Pietro, Barbara; Grasso, Cristina; Schillaci, Orazio.

In: Nuclear Medicine Communications, Vol. 33, No. 6, 06.2012, p. 563-570.

Research output: Contribution to journalArticle

Calabria, F, Chiaravalloti, A, Di Pietro, B, Grasso, C & Schillaci, O 2012, 'Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT', Nuclear Medicine Communications, vol. 33, no. 6, pp. 563-570. https://doi.org/10.1097/MNM.0b013e328351d566
Calabria F, Chiaravalloti A, Di Pietro B, Grasso C, Schillaci O. Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT. Nuclear Medicine Communications. 2012 Jun;33(6):563-570. https://doi.org/10.1097/MNM.0b013e328351d566
Calabria, Ferdinando ; Chiaravalloti, Agostino ; Di Pietro, Barbara ; Grasso, Cristina ; Schillaci, Orazio. / Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT. In: Nuclear Medicine Communications. 2012 ; Vol. 33, No. 6. pp. 563-570.
@article{ea9db8c67e0f4b5bbcccd8c4994e44f1,
title = "Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT",
abstract = "The objective of this study was to give an overview of the potential clinical utility of [ 18F]-L-dihydroxyphenylalanine ( 18F-DOPA) PET and PET/CT for imaging of brain tumors. Review articles and reference lists were used to supplement the search findings. 18F-DOPA has been investigated as a PET tracer for primary brain tumors, metastases of somatic cancer, and evaluation of relapse of pathology in patients with brain tumor after surgery and/or radiotherapy on the basis of enhanced cell proliferation. Available studies have provided encouraging preliminary results for diagnosis of brain tumors and relapse after surgery/radiotherapy. In the brain, excellent discrimination between tumor and normal tissue can be achieved because of the low physiological uptake of 18F-DOPA and the high ratio between tumor and normal hemispheric tissue. Information on evaluation of brain metastases is limited but encouraging. PET and PET/CT with 18F-DOPA are useful in diagnosing primary brain tumors and should be recommended in the diagnosis of relapse of disease after surgical treatment and/or radiotherapy. Semiquantitative analysis could improve diagnosis while correlative imaging with MRI is essential. Limits are due to low knowledge of potential pitfalls.",
keywords = "[ F]-L-dihydroxyphenylalanine, brain metastases, brain tumors, molecular imaging, PET/CT, recurrence",
author = "Ferdinando Calabria and Agostino Chiaravalloti and {Di Pietro}, Barbara and Cristina Grasso and Orazio Schillaci",
year = "2012",
month = "6",
doi = "10.1097/MNM.0b013e328351d566",
language = "English",
volume = "33",
pages = "563--570",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT

AU - Calabria, Ferdinando

AU - Chiaravalloti, Agostino

AU - Di Pietro, Barbara

AU - Grasso, Cristina

AU - Schillaci, Orazio

PY - 2012/6

Y1 - 2012/6

N2 - The objective of this study was to give an overview of the potential clinical utility of [ 18F]-L-dihydroxyphenylalanine ( 18F-DOPA) PET and PET/CT for imaging of brain tumors. Review articles and reference lists were used to supplement the search findings. 18F-DOPA has been investigated as a PET tracer for primary brain tumors, metastases of somatic cancer, and evaluation of relapse of pathology in patients with brain tumor after surgery and/or radiotherapy on the basis of enhanced cell proliferation. Available studies have provided encouraging preliminary results for diagnosis of brain tumors and relapse after surgery/radiotherapy. In the brain, excellent discrimination between tumor and normal tissue can be achieved because of the low physiological uptake of 18F-DOPA and the high ratio between tumor and normal hemispheric tissue. Information on evaluation of brain metastases is limited but encouraging. PET and PET/CT with 18F-DOPA are useful in diagnosing primary brain tumors and should be recommended in the diagnosis of relapse of disease after surgical treatment and/or radiotherapy. Semiquantitative analysis could improve diagnosis while correlative imaging with MRI is essential. Limits are due to low knowledge of potential pitfalls.

AB - The objective of this study was to give an overview of the potential clinical utility of [ 18F]-L-dihydroxyphenylalanine ( 18F-DOPA) PET and PET/CT for imaging of brain tumors. Review articles and reference lists were used to supplement the search findings. 18F-DOPA has been investigated as a PET tracer for primary brain tumors, metastases of somatic cancer, and evaluation of relapse of pathology in patients with brain tumor after surgery and/or radiotherapy on the basis of enhanced cell proliferation. Available studies have provided encouraging preliminary results for diagnosis of brain tumors and relapse after surgery/radiotherapy. In the brain, excellent discrimination between tumor and normal tissue can be achieved because of the low physiological uptake of 18F-DOPA and the high ratio between tumor and normal hemispheric tissue. Information on evaluation of brain metastases is limited but encouraging. PET and PET/CT with 18F-DOPA are useful in diagnosing primary brain tumors and should be recommended in the diagnosis of relapse of disease after surgical treatment and/or radiotherapy. Semiquantitative analysis could improve diagnosis while correlative imaging with MRI is essential. Limits are due to low knowledge of potential pitfalls.

KW - [ F]-L-dihydroxyphenylalanine

KW - brain metastases

KW - brain tumors

KW - molecular imaging

KW - PET/CT

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=84860837855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860837855&partnerID=8YFLogxK

U2 - 10.1097/MNM.0b013e328351d566

DO - 10.1097/MNM.0b013e328351d566

M3 - Article

C2 - 22395034

AN - SCOPUS:84860837855

VL - 33

SP - 563

EP - 570

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 6

ER -